[Nerve growth factor and neurological diseases]

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• Nerve Growth Factor (NGF) plays crucial roles both within and outside the nervous system.
• Recent clinical studies highlight NGF's therapeutic potential for neurodegenerative disorders.
• Accurate measurement methods are essential for monitoring NGF levels during treatment.

Purpose of the Study:

• To establish an immunoenzymatic method for quantifying human serum NGF levels.
• To evaluate NGF concentrations in patients with various neurological conditions.
• To assess NGF levels in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Huntington's chorea (HC).

Main Methods:

• Utilized a double-site immune-enzymatic assay for NGF measurement.
• Employed a murine 27/21 anti-beta-NGF monoclonal antibody as a coating and conjugate agent.
• Incorporated a blocking step with excess antibody to optimize assay sensitivity.

Main Results:

• A moderate decrease in beta-NGF serum levels was observed in patients with ALS and MS.
• Statistically significant reductions in beta-NGF levels were detected in patients with PD and HC.
• The assay demonstrated sensitivity to variations in NGF concentrations.

Conclusions:

• Significantly reduced NGF levels in PD and HC patients may indicate impaired NGF utilization.
• These findings suggest a potential link between NGF dysregulation and the pathophysiology of PD and HC.
• Further research is warranted to explore the implications of altered NGF levels in neurological diseases.